Normal Tissue Toxicity After Stereotactic Body Radiation Therapy
Author Information
Author(s): Michael T Milano, Louis S Constine, Paul Okunieff
Primary Institution: University of Rochester Medical Center
Hypothesis
What are the risks of late toxicity associated with stereotactic body radiation therapy (SBRT)?
Conclusion
SBRT reduces the volume of normal tissue exposed to therapeutic doses, allowing for larger fractional dose delivery, but further studies are needed to optimize treatment and understand late toxicity.
Supporting Evidence
- SBRT allows for higher doses of radiation to be delivered while minimizing damage to surrounding healthy tissue.
- Clinical data suggests SBRT is safe in most cases, but more research is needed.
- The long-term effects of SBRT on normal tissues are not fully understood.
Takeaway
Doctors use a special type of radiation therapy called SBRT to treat tumors while trying to protect healthy tissue. It works well, but they need to study it more to make sure it's safe.
Methodology
This review discusses the principles of SBRT, its radiobiology, and outcomes from clinical trials focusing on late toxicity.
Limitations
Limited clinical outcome data on late toxicity and dose-volume constraints.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website